Neuroblastoma: biological insights into a clinical enigma

@article{Brodeur2003NeuroblastomaBI,
  title={Neuroblastoma: biological insights into a clinical enigma},
  author={Garrett M. Brodeur},
  journal={Nature Reviews Cancer},
  year={2003},
  volume={3},
  pages={203-216}
}
  • G. Brodeur
  • Published 2003
  • Medicine
  • Nature Reviews Cancer
Neuroblastoma is a tumour derived from primitive cells of the sympathetic nervous system and is the most common solid tumour in childhood. Interestingly, most infants experience complete regression of their disease with minimal therapy, even with metastatic disease. However, older patients frequently have metastatic disease that grows relentlessly, despite even the most intensive multimodality therapy. Recent advances in understanding the biology and genetics of neuroblastomas have allowed… Expand

Paper Mentions

Interventional Clinical Trial
The European study, LINES 2009 (Low and Intermediate Risk Neuroblastoma European Study), groups together in a single protocol the treatment of all patients with "non high risk… Expand
ConditionsLOW AND INTERMEDIATE PAEDIATRIC NEUROBLASTOMA AND NEONATAL SUPRARENAL MASSES
InterventionDrug
Neuroblastoma: biology, prognosis, and treatment.
TLDR
This article summarizes the understanding of neuroblastoma biology and prognostic features and discusses their impact on current and proposed risk stratification schemas, risk-based therapeutic approaches, and the development of novel therapies for patients at high risk for failure. Expand
Neuroblastoma: biology, prognosis, and treatment.
TLDR
This article summarizes the understanding of neuroblastoma biology and prognostic features and discusses their impact on current and proposed risk stratification schemas, risk-based therapeutic approaches, and the development of novel therapies for patients at high risk for failure. Expand
Neuroblastoma: The impact of biology and cooperation leading to personalized treatments
TLDR
The largest national treatment groups from North America, Europe and Japan have formed the International Neuroblastoma Risk Group Task Force (INRG) to identify prognostic factors, to understand the mechanisms of tumorigenesis in this rare disease and to develop multi-modality therapies to improve outcomes and decrease treatment-related toxicities. Expand
The connections between neural crest development and neuroblastoma.
TLDR
This review focuses on the development of the peripheral trunk neural crest, the current understanding of how developmental factors may contribute to NB and on recent advances in the identification of important genetic lesions and signaling pathways involved in NB tumorigenesis and metastasis. Expand
Genomic Profiling of Neuroblastoma Tumors – Prognostic Impact of Genomic Aberrations
TLDR
A dense genome-wide copy number analysis with microarrays is used to analyze a large number of neuroblastoma tumors with the aim of improving patient stratification and reveal new features of the tumors. Expand
Neuroblastoma—A Neural Crest Derived Embryonal Malignancy
TLDR
Factors and processes within the neural crest that when dysregulated have the potential to be initiators or drivers of neuroblastoma development are discussed and will give valuable information for the development of medicines that specifically target molecules within Neuroblastoma cells. Expand
Exploring novel therapeutic strategies in neuroblastoma
Neuroblastoma (NB) is the most frequently diagnosed extracranial tumour in children, which arises from transient embryonal tissue of the neural crest that fails to complete terminal differentiationExpand
Neuroblastoma: developmental biology, cancer genomics and immunotherapy
TLDR
The key discoveries in the developmental biology, molecular genetics and immunology of neuroblastoma are discussed, as well as new translational tools for bringing these promising scientific advances into the clinic. Expand
The role of genetic and epigenetic alterations in neuroblastoma disease pathogenesis
TLDR
The main genetic factors responsible for these diverse clinical phenotypes in neuroblastoma are described, the chronology of their discovery, and the impact on patient prognosis are described. Expand
Molecular characterization and classification of neuroblastoma.
TLDR
Advances in techniques that efficiently specify both comprehensive genetic and gene-expression alterations of neuroblastoma tumors have provided molecular markers that indicate tumor behavior and patient outcome with very high accuracy, and this knowledge will help to establish therapeutic strategies specifically targeting molecular key factors of Neuroblastoma tumor progression. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 213 REFERENCES
Mechanism and relevance of ploidy in neuroblastoma
TLDR
A hypothesis is offered that explains how the ploidy state of the tumor plays a fundamental role in this heterogeneity, and why various prognostic factors are correlated with each other. Expand
Genetic parameters of neuroblastomas.
TLDR
From the analysis of tumors at the cytogenetic and molecular level non-random genetic changes have been identified, including ploidy changes, amplification of the oncogene MYCN, deletion of chromosome 1p, gains of chromosome arm 17q, and deletions of 11q as well as of other genomic regions that allow tumors to be classified into subsets with distinct biological features and clinical behavior. Expand
Biology and genetics of human neuroblastomas.
TLDR
It is proposed that neuroblastomas may be classified into three subsets with distinct biological features and clinical behavior, which allows more appropriate selection of therapeutic intensity to minimize side effects in those with a favorable outcome but optimize the chance of cure in those requiring aggressive treatment. Expand
Spontaneous regression of neuroblastoma.
Case of spontaneous regression of neuroblastoma continue to occur in the present multimodal therapy era at institutions where physicians are prepared to withhold treatment on certain patients withExpand
Role of ploidy, chromosome 1p, and Schwann cells in the maturation of neuroblastoma.
TLDR
Near-trip-loidy of neuroblastoma cells and intact chromosome 1 are presumably genetic prerequisites for spontaneous organoid maturation, because the authors found no diploidy or chromosome 1 depletions in the neuronal cells of spontaneously maturing neuroblastomas. Expand
No CDKN2 mutations in neuroblastomas.
TLDR
It is concluded that disruption of the CDKN2 gene is not required for malignant transformation of human neuroblastomas and no homozygous deletions were detected and there was no loss of heterozygosity at the closely linked IFNA locus. Expand
Clinical relevance of tumor cell ploidy and N-myc gene amplification in childhood neuroblastoma: a Pediatric Oncology Group study.
  • A. Look, F. A. Hayes, +5 authors G. Brodeur
  • Medicine
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 1991
TLDR
In children younger than 2 years with disseminated neuroblastoma, tumor cell ploidy and N-myc gene copy number provide complementary prognostic information that will distinguish patients who can be cured on current regimens from those who require new treatment strategies. Expand
Clinical relevance of CD44 cell-surface expression and N-myc gene amplification in a multicentric analysis of 121 pediatric neuroblastomas.
  • V. Combaret, N. Gross, +5 authors M. Favrot
  • Medicine
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 1996
TLDR
The analysis of CD44 cell-surface expression must be recommended as an additional biologic marker in the initial staging of the disease. Expand
First line targeted radiotherapy, a new concept in the treatment of advanced stage neuroblastoma.
TLDR
Previously untreated advanced stage neuroblastoma patients treated with [131I]meta-iodobenzylguanidine (MIBG) found this approach is feasible, comparable to multidrug chemotherapy in efficacy and less toxic. Expand
Inverse relationship between trk expression and N-myc amplification in human neuroblastomas.
TLDR
Tk expression was associated with an absence of N-myc amplification, lower disease stage, lower patient age, and favorable outcome, and trk expression may be more likely to differentiate, regress spontaneously, or respond well to therapy. Expand
...
1
2
3
4
5
...